‘Infection Source Blocking and Infected Cell Treatment’ Bidirectional Mechanism Expected to Deliver Excellent Therapeutic Effects
High Recovery Effects on Acute Pneumonia and Pulmonary Fibrosis Symptoms through Nox Inhibition Function
[Asia Economy Reporter Hyungsoo Park] Aptabio, a developer of anticancer and diabetic complication treatments, is seeing a surge in its stock price. The news that a candidate substance for treating COVID-19 has proven effective appears to have influenced the stock price.
At 9:11 a.m. on the 16th, Aptabio was trading at 25,050 KRW, up 7.05% from the previous trading day.
On the same day, Aptabio announced that through cell experiments, its NOX inhibitor treatment ‘APX-115’ was confirmed to be effective in treating COVID-19.
‘APX-115’ was found to fundamentally block infection by preventing the COVID-19 virus from penetrating cells and was also effective in treating infected cells. The NOX inhibitor APX-115 showed efficacy against acute pneumonia and pulmonary fibrosis, major symptoms of COVID-19.
An Aptabio official stated, "The virus-killing effect of APX-115 is known to be about 30% of that of Remdesivir," adding, "This treatment has two additional mechanisms of action besides its direct RNA therapeutic effect."
They continued, "The three mechanisms?blocking viral penetration into cells, treating pneumonia, and treating pulmonary fibrosis?work simultaneously, resulting in excellent efficacy in treating COVID-19 infections."
The official also added, "APX-115 has already completed Phase 1 clinical trials in Europe," confirming "there were no safety or side effect issues."
Since the treatment fundamentally blocks viral penetration into cells, it is expected to be applicable to patients who are unresponsive to existing treatments like Remdesivir due to variant viruses. Aptabio plans to conduct Phase 2 clinical trials targeting COVID-19 patients to verify the efficacy and optimal dosage of APX-115.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
